Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
Roberto Anichini,1 Sabrina Cosimi,2 Alberto Di Carlo,3 Paola Orsini,4 Alessandra De Bellis,1 Giuseppe Seghieri,1 Flavia Franconi,5 Fabio Baccetti6 1Diabetes Unit, Spedali Riuniti, Pistoia, Italy; 2Diabetes Unit, Hospital of Versilia, Camaiore (LU), Italy; 3Diabetes Unit, Hospital of Lucca, Italy; 4D...
Guardado en:
Autores principales: | Anichini R, Cosimi S, Di Carlo A, Orsini P, De Bellis A, Seghieri G, Franconi F, Baccetti F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ed8b4944f710455799e614e25aa957db |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
por: Ostenson CG, et al.
Publicado: (2013) -
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
por: Gurney K, et al.
Publicado: (2012) -
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016) -
Exenatide improves glucocorticoid-induced glucose intolerance in mice
por: Ruiying Zhao, et al.
Publicado: (2011) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)